
Please try another search
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverematinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), Dupert (fulzerasib), DOVBLERON (taletrectinib), Jaypirca (pirtobrutinib), limertinib, and SYCUME (teprotumumab N01 injection). The company is also developing three new drugs, which are under regulatory review; four assets in Phase 3 and pivotal clinical trials; and 15 molecules in early clinical stage. In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People’s Republic of China.
Name | Age | Since | Title |
---|---|---|---|
De-Chao Yu | 60 | 2011 | Co-Founder, Chairman & CEO |
Qian Zhang | 37 | 2024 | Executive Director |
Charles Leland Cooney | 80 | 2015 | Member of CMC Strategic Advisory Board & Independent Non-Executive Director |
I-Yin Hsu | 49 | 2018 | Independent Non-Executive Director |
Carlos Garcia-Echeverria | 60 | 2021 | Member of Scientific Advisory Board |
Gary J. Zieziula | 70 | 2022 | Independent Non-Executive Director |
Chiang Syin | 69 | - | Member of CMC Strategic Advisory Board |
David LaPre | 73 | - | Member of CMC Strategic Advisory Board |
Lewis L. Lanier | - | 2021 | Member of Scientific Advisory Board |
Lawrence Fong | - | 2021 | Member of Scientific Advisory Board |
Erwin Vanhaecke | - | - | Member of CMC Strategic Advisory Board |
Shuyun Chen | 50 | 2024 | Lead Independent Non-Executive Director |
Qian Zhang | 38 | 2019 | Chief People Officer, GM & Executive Director |
Hao Xi Ede | 66 | 2024 | Executive Director & Fund Managing Partner |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review